Seer (NASDAQ:SEER) vs. PerkinElmer (NYSE:PKI) Financial Review

0

Seeing (NASDAQ: SEERGet a rating) and Perkin Elmer (NYSE: PKIGet a rating) are both medical companies, but which is the higher value? We’ll compare the two companies based on valuation strength, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Volatility and risk

Seer has a beta of 2.27, indicating its stock price is 127% more volatile than the S&P 500. In comparison, PerkinElmer has a beta of 1.13, indicating its stock price is 13 % more volatile than the S&P 500.

Insider and Institutional Ownership

86.9% of Seer shares are held by institutional investors. By comparison, 89.3% of PerkinElmer shares are held by institutional investors. 18.0% of Seer’s stock is held by insiders of the company. By comparison, 0.5% of PerkinElmer’s stock is held by company insiders. Strong institutional ownership indicates that large fund managers, hedge funds, and endowments believe a company will outperform the market over the long term.

Profitability

This table compares the net margins, return on equity and return on assets of Seer and PerkinElmer.

Net margins Return on equity return on assets
Seeing -794.43% -15.44% -14.71%
Perkin Elmer 14.54% 18.98% 9.06%

Analyst Recommendations

This is a summary of current ratings and price targets for Seer and PerkinElmer, as provided by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Seeing 0 1 1 0 2.50
Perkin Elmer 1 1 4 0 2.50

Seer currently has a consensus target price of $21.00, indicating a potential upside of 133.33%. PerkinElmer has a consensus target price of $154.71, indicating a potential upside of 1.01%. Given Seer’s likely higher upside, equity research analysts clearly believe Seer is more favorable than PerkinElmer.

Benefits and evaluation

This table compares gross revenue, earnings per share and valuation of Seer and PerkinElmer.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Seeing $6.62 million 84.89 -$71.17 million ($1.27) -7.09
Perkin Elmer $5.07 billion 3.81 $943.16 million $6.11 25.07

PerkinElmer has higher revenues and profits than Seer. Seer trades at a lower price-to-earnings ratio than PerkinElmer, indicating that it is currently the more affordable of the two stocks.

Summary

PerkinElmer beats Seer on 9 out of 13 factors compared between the two stocks.

About LED

(Get a rating)

Seer, Inc., a life sciences company, engages in the development and commercialization of products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that includes consumables, automation instrumentation and software that enables researchers to conduct proteomics studies in therapeutic and diagnostic research and clinical trials. The Company intends to sell its products for research purposes, which covers academic institutions, life sciences and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

About PerkinElmer

(Get a rating)

Perkin Elmer logoPerkinElmer, Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, computational and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life science research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions and services for the environmental, food and industrial markets that enable its customers to understand the health characteristics of various aspects, including the air, water and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricants, petrochemical and polymer industries. The Diagnostics segment provides instruments, reagents, analysis platforms and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. . Its products are used to test and screen for genetic abnormalities, disorders and diseases, including Down syndrome, hypothyroidism, muscular dystrophy, infertility and various metabolic conditions. This segment also develops technologies that enable and support genomics workflows using protein-coupled receptors and next-generation DNA sequencing for applications in oncology, immunodiagnostics and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private health organizations, physicians and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.



Get news and reviews for Seer Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Seer and related companies with MarketBeat.com’s free daily email newsletter.

Share.

About Author

Comments are closed.